Page 131 - 2021_07-Haematologica-web

Study of Ruxolitinib as a front-line therapy for pediatric HLH
Funding
The authors would like to thank grants from the National Natural Science Foundation of China (No. 81800189); Beijing Municipal Administration of Hospitals’ Youth Programme (QML20181205); the Scientific Research Common Program of
KM201910025011); the Special Fund of The Pediatric Medical Coordinated Development Center of Beijing Municipal Administration (No. XTZD20180202); National Science and Technology Key Projects (No. 2017ZX09304029003); Guangdong Province Key Laboratory of Popular High Performance Computers of Shenzhen University (SZU-GDPHPCL2017) .
Beijing Municipal Commission of
References
1. Thomas W, Veer MV, Haemophagocytic lymphohistiocytosis: an elusive syndrome. Clin Med (Lond). 2016; 16(5):432-436.
2.Trottestam H, Horne A, Aricò M, et al. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. Blood. 2011; 118(17):4577-4584.
3.Bergsten E, Horne A, Aricó M, et al. Confirmed efficacy of etoposide and dexam- ethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. Blood. 2017;130(25):2728-2738.
4.Pui CH, Ribeiro RC, Hancock ML, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lym- phoblastic leukemia. N Engl J Med. 1991; 325(24):1682-1687.
5.Henter JI, Elinder G, Lübeck PO, Ost A. Myelodysplastic syndrome following epipodophyllotoxin therapy in familial hemophagocytic lymphohistiocytosis. Pediatr Hematol Oncol. 1993;10(2):163-168.
6.Kitazawa J, Ito E, Arai K, Yokoyama M, Fukayama M, Imashuku S. Secondary acute myelocytic leukemia after successful chemotherapy with etoposide for Epstein- Barr virus-associated hemophagocytic lym- phohistiocytosis. Med Pediatr Oncol. 2001; 37(2):153-154.
7.Miettunen PM, Narendran A, Jayanthan A, Behrens EM, Cron RQ. Successful treatment of severe paediatric rheumatic disease-asso- ciated macrophage activation syndrome with interleukin-1 inhibition following con- ventional immunosuppressive therapy: case series with 12 patients. Rheumatology (Oxford). 2011;50(2):417-419.
8.Locatelli F, Jordan MB, Allen C, et al. Emapalumab in children with primary hemophagocytic lymphohistiocytosis. N Engl J Med. 2020;382(19):1811-1822.
9. Villarino AV, Kanno Y, Ferdinand JR, O'Shea JJ. Mechanisms of Jak/STAT signaling in immunity and disease. J Immunol. 2015;194(1):21-27.
10.Kiu H, Nicholson SE. Biology and signifi- cance of the JAK/STAT signalling pathways. Growth Factors. 2012;30(2):88-106.
Education (No.
Besser M.
11. Das R, Guan P, Sprague L, et al. Janus kinase inhibition lessens inflammation and amelio- rates disease in murine models of hemo- phagocytic lymphohistiocytosis. Blood. 2016;127(13):1666-1675.
12. Maschalidi S, Sepulveda FE, Garrigue A, Fischer A, de Saint Basile G. Therapeutic effect of JAK1/2 blockade on the manifesta- tions of hemophagocytic lymphohistiocyto- sis in mice. Blood. 2016;128(1):60-71.
13.Albeituni S, Verbist KC, Tedrick PE, et al. Mechanisms of action of ruxolitinib in murine models of hemophagocytic lympho- histiocytosis. Blood. 2019;134(2):147-159.
14. Sin JH, Zangardi ML. Ruxolitinib for second- ary hemophagocytic lymphohistiocytosis: first case report. Hematol Oncol Stem Cell Ther. 2019;12(3):166-170.
15. Broglie L, Pommert L, Rao S, et al. Ruxolitinib for treatment of refractory hemo- phagocytic lymphohistiocytosis. Blood Adv. 2017;1(19):1533-1536.
16. Wang J, Wang Y, Wu L, et al. Ruxolitinib for refractory/relapsed hemophagocytic lym- phohistiocytosis. Haematologica. 2020;105(5):e210-e212.
17. Slostad J, Hoversten P, Haddox CL, Cisak K, Paludo J, Tefferi A. Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: a single patient experi- ence. Am J Hematol. 2018;93(2):E47-e49.
18. Zandvakili I, Conboy CB, Ayed AO, Cathcart-Rake EJ, Tefferi A. Ruxolitinib as first-line treatment in secondary hemo- phagocytic lymphohistiocytosis: a second experience. Am J Hematol. 2018;93(5):E123- e125.
19.Ahmed A, Merrill SA, Alsawah F, et al. Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial. Lancet Haematol. 2019;6(12):e630-e637.
20.Henter JI, Horne A, Aricó M, et al. HLH- 2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediat Blood Cancer. 2007;48(2):124-131.
21.Marsh RA, Allen CE, McClain KL, et al. Salvage therapy of refractory hemophago- cytic lymphohistiocytosis with alemtuzum- ab. Pediat Blood Cancer. 2013;60(1):101-109.
22.Marsh RA, Jordan MB, Talano JA, et al. Salvage therapy for refractory hemophago-
cytic lymphohistiocytosis: a review of the published experience. Pediat Blood Cancer. 2017;64(4).
23. Lounder DT, Bin Q, de Min C, Jordan MB. Treatment of refractory hemophagocytic lymphohistiocytosis with emapalumab despite severe concurrent infections. Blood Adv. 2019;3(1):47-50.
24. Verstovsek S, Mesa RA, Gotlib J, et al. A dou- ble-blind, placebo-controlled trial of ruxoli- tinib for myelofibrosis. N Engl J Med. 2012;366(9):799-807.
25. Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372(5):426-435.
26. Przepiorka D, Luo L, Subramaniam S, et al. FDA approval summary: ruxolitinib for treat- ment of steroid-refractory acute graft-versus- host disease. Oncologist. 2020;25(2):e328- e334.
27.Zeiser R, Burchert A, Lengerke C, et al. Ruxolitinib in corticosteroid-refractory graft- versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia. 2015;29(10):2062-2068.
28. Pemmaraju N, Kantarjian H, Kadia T, et al. A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015;15(3):171-176.
29.Dao KT, Gotlib J, Deininger MMN, et al. Efficacy of ruxolitinib in patients with chron- ic neutrophilic leukemia and atypical chronic myeloid leukemia. J Clin Oncol. 2020; 38(10):1006-1018.
30. González Vicent M, Molina B, González de Pablo J, Castillo A, Díaz M. Ruxolitinib treat- ment for steroid refractory acute and chronic graft vs host disease in children: Clinical and immunological results. Am J Hematol. 2019;94(3):319-326.
31. Wang J, Wang Y, Wu L, Zhang J, Lai W, Wang Z. PEG-aspargase and DEP regimen combi- nation therapy for refractory Epstein-Barr virus-associated hemophagocytic lympho- histiocytosis. J Hematol Oncol. 2016;9(1):84.
32. Li H, Liu S, Hu J, et al. Epstein-Barr virus lytic reactivation regulation and its pathogenic role in carcinogenesis. Int J Biol Sci. 2016; 12(11):1309-1318.
haematologica | 2021; 106(7)
1901